A 6 Month, Prospective, Randomized, Double Blind, Placebo-Controlled, Parallel Group, Multiple Center Trial To Evaluate The Efficacy And Safety Of Fragmin In The Treatment Of Chronic Neuroischaemic Foot Ulcers In Diabetic Patients.

Trial Profile

A 6 Month, Prospective, Randomized, Double Blind, Placebo-Controlled, Parallel Group, Multiple Center Trial To Evaluate The Efficacy And Safety Of Fragmin In The Treatment Of Chronic Neuroischaemic Foot Ulcers In Diabetic Patients.

Completed
Phase of Trial: Phase II/III

Latest Information Update: 27 Aug 2014

At a glance

  • Drugs Dalteparin sodium (Primary)
  • Indications Diabetic foot ulcer; Embolism and thrombosis
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms FEENICS
  • Sponsors Pfizer
  • Most Recent Events

    • 28 Apr 2012 Planned patient number for extension trial is 215 as reported by European Clinical Trials Database record (EudraCT2008-001566-90).
    • 28 Apr 2012 Planned patient number for extension trial is 215 as reported by European Clinical Trials Database record (EudraCT2008-001566-90).
    • 24 Mar 2011 Actual end date (October 2010) of extension trial (NCT00765063) added as reported by ClinicalTrials.gov
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top